Iodine-131 iobenguane  ***DISCONTINUED 2024***

Approved Use:  indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.
Dose: See below
​
Brand Name: Azedra®
Manufacturer: Lantheus/Progenics Pharmaceuticals
Package Insert
​Product Website
How Supplied: 15 mCi/mL 

• Dosimetric vial: 2 mL (30 mCi)
• Therapeutic vial: 22.5 mL (337.5 mCi)

Calibration:
Expiration: 6 days after calibration or 8 hours after product is removed from freezer
Storage: ***store frozen*** -70° C (-94° F) 
NDC #: 

• Dosimetric vial: 71258-015-02
• Therapeutic vial: 71258-015-22

Press Release July 2018 (FDA approval)
Dosing & Administration Guide
Recommended Dosimetric Dose: 

• Patients >50 kg: 5 or 6 mCi
• Patients ≤50 kg: 0.1 mCi/kg

Recommended Therapeutic Dose for Each Therapeutic Cycle (a total of 2 therapeutic doses at least 90 days apart):

• Patients >62.5 kg: 500 mCi
• Patients ≤62.5 kg: 8 mCi/kg